TriangleCDX-1140 + CDX-301 + PLD (NCT05029999)
CDX-1140 + CDX-301 + PLD trial for Metastatic HER2-Negative Breast Cancer (NCT05029999). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or unresectable HER2 negative breast cancer.
The idea: combine two immunotherapy drugs, CDX-1140, a CD40 agonist given by vein, and CDX-301, a Flt3 ligand given as injections under the skin, with standard pegylated liposomal doxorubicin chemotherapy.
This phase 1 study plans 30 patients and looks at dose limiting side effects and a safe dose and schedule. At UT Southwestern Medical Center in Dallas, Sangeetha Reddy leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.